High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
Name:
journal.pone.0193694.pdf
Size:
8.521Mb
Format:
PDF
Description:
Full text, Open Access article
Authors
Yu, KTaylor, J
Pathmanaban, O
Youshani, A
Beyit, D
Dutko-Gwozdz, J
Benson, R
Griffiths, G
Peers, I
Cueppens, P
Telfer, B
Williams, K
McBain, Catherine A
Kamaly-Asl, I
Bigger, B
Affiliation
Brain Tumour Research Group, Stem Cell and Neurotherapies Laboratory, Division of Cell Matrix Biology & Regenerative Medicine, University of Manchester, Manchester, United KingdomIssue Date
2018
Metadata
Show full item recordAbstract
Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes remain poor. First line treatment is well established, however disease invariably recurs and improving prognosis is challenging. With the aim of personalizing therapy at recurrence, we have established a high content screening (HCS) platform to analyze the sensitivity profile of seven patient-derived cancer stem cell lines to 83 FDA-approved chemotherapy drugs, with and without irradiation.Citation
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma. 2018, 13(3): e0193694 PLoS OneJournal
PloS OneDOI
10.1371/journal.pone.0193694PubMed ID
29499065Type
ArticleLanguage
enISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0193694
Scopus Count
Collections
Related articles
- A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses.
- Authors: Gomez-Roman N, Stevenson K, Gilmour L, Hamilton G, Chalmers AJ
- Issue date: 2017 Feb 1
- High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
- Authors: Hothi P, Martins TJ, Chen L, Deleyrolle L, Yoon JG, Reynolds B, Foltz G
- Issue date: 2012 Oct
- Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
- Authors: Skaga E, Kulesskiy E, Fayzullin A, Sandberg CJ, Potdar S, Kyttälä A, Langmoen IA, Laakso A, Gaál-Paavola E, Perola M, Wennerberg K, Vik-Mo EO
- Issue date: 2019 Jun 25
- Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
- Authors: Buccarelli M, Marconi M, Pacioni S, De Pascalis I, D'Alessandris QG, Martini M, Ascione B, Malorni W, Larocca LM, Pallini R, Ricci-Vitiani L, Matarrese P
- Issue date: 2018 Aug 6
- Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma.
- Authors: Taylor JT, Ellison S, Pandele A, Wood S, Nathan E, Forte G, Parker H, Zindy E, Elvin M, Dickson A, Williams KJ, Karabatsou K, McCabe M, McBain C, Bigger BW
- Issue date: 2020 Sep 29